Trial Profile
Phase I Trial of Twice Weekly IV IL [interleukin]-12 Plus Low-Dose Subcutaneous IL-2 in Patients With Advanced Malignancies
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Aldesleukin (Primary) ; Edodekin alfa (Primary)
- Indications Solid tumours
- Focus Therapeutic Use
- 28 Sep 2005 New trial record.